Efedra Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 06-07-2024
- Paid Up Capital ₹ 0.10 M
as on 06-07-2024
- Company Age 7 Year, 15 Days
- Last Filing with ROC 31 Mar 2023
- Revenue 67.60%
(FY 2022)
- Profit -27.34%
(FY 2022)
- Ebitda -37.81%
(FY 2022)
- Net Worth 48.12%
(FY 2022)
- Total Assets 51.62%
(FY 2022)
About Efedra Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Mohuya Chakroborty and Arindam Bhattacharya serve as directors at the Company.
- CIN/LLPIN
U24239WB2017PTC223778
- Company No.
223778
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Dec 2017
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
Kolkata, West Bengal, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Efedra Pharmaceuticals Private Limited offer?
Efedra Pharmaceuticals Private Limited offers a wide range of products and services, including Anti Infective Drugs & Medicines, Antibacterial Drugs, Anti Infective Agent.
Who are the key members and board of directors at Efedra Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mohuya Chakroborty  | Director | 08-Dec-2017 | Current |
| Arindam Bhattacharya | Director | 08-Dec-2017 | Current |
Financial Performance of Efedra Pharmaceuticals.
Efedra Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 67.6% increase. The company also saw a substantial fall in profitability, with a 27.34% decrease in profit. The company's net worth Soared by an impressive increase of 48.12%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Efedra Pharmaceuticals?
In 2022, Efedra Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Efedra Pharmaceuticals?
Efedra Pharmaceuticals has a workforce of 26 employees as of Apr 02, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Efedra Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Efedra Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
